Biodistribution Data for 18F-FB-NAPamide in C57BL/6 Mice Bearing Subcutaneously Xenotransplanted B16/F10 Murine Melanoma and Fox Chase Scid Mice Bearing A375M Human Melanoma
| B16/F10 | A375M | ||||
|---|---|---|---|---|---|
| 18F-FB-NAPamide | 1 h | 1-h block | 4 h | 1 h | 1-h block |
| Tumor | 1.19 ± 0.11 | 0.61 ± 0.09 | 0.25 ± 0.05 | 0.46 ± 0.11 | 0.33 ± 0.02 |
| Blood | 0.65 ± 0.07 | 0.51 ± 0.15 | 0.07 ± 0.01 | 0.38 ± 0.18 | 0.28 ± 0.06 |
| Muscle | 0.21 ± 0.02 | 0.20 ± 0.02 | 0.04 ± 0.02 | 0.22 ± 0.05 | 0.20 ± 0.01 |
| Skin | 0.35 ± 0.04 | 0.31 ± 0.06 | 0.09 ± 0.07 | 0.35 ± 0.12 | 0.20 ± 0.04 |
| Bone | 0.20 ± 0.02 | 0.18 ± 0.04 | 0.14 ± 0.13 | 0.19 ± 0.06 | 0.13 ± 0.01 |
| Heart | 0.28 ± 0.05 | 0.21 ± 0.05 | 0.05 ± 0.02 | 0.22 ± 0.10 | 0.19 ± 0.02 |
| Liver | 0.79 ± 0.25 | 0.64 ± 0.18 | 0.13 ± 0.14 | 0.53 ± 0.20 | 0.43 ± 0.08 |
| Lung | 0.50 ± 0.06 | 0.54 ± 0.01 | 0.10 ± 0.04 | 0.40 ± 0.15 | 0.54 ± 0.09 |
| Kidney | 6.03 ± 1.53 | 5.52 ± 1.93 | 0.53 ± 0.38 | 2.79 ± 1.09 | 2.13 ± 0.38 |
| Spleen | 0.20 ± 0.03 | 0.16 ± 0.02 | 0.09 ± 0.09 | 0.27 ± 0.08 | 0.41 ± 0.31 |
| Brain | 0.05 ± 0.01 | 0.05 ± 0.02 | 0.01 ± 0.01 | 0.03 ± 0.02 | 0.02 ± 0.00 |
| Intestine | 8.07 ± 7.78 | 20.62 ± 25.94 | 0.12 ± 0.08 | 7.57 ± 5.12 | 0.91 ± 0.30 |
| Stomach | 0.34 ± 0.04 | 1.65 ± 0.95 | 0.29 ± 0.23 | 1.59 ± 2.10 | 0.56 ± 0.56 |
| Pancreas | 0.24 ± 0.06 | 0.18 ± 0.07 | 0.16 ± 0.18 | 0.26 ± 0.12 | 0.40 ± 0.33 |
| Tumor/blood ratio | 1.86 ± 0.44 | 1.23 ± 0.19 | 3.60 ± 0.37 | 1.34 ± 0.39 | 1.24 ± 0.31 |
| Tumor/muscle ratio | 5.63 ± 0.34 | 3.10 ± 0.19 | 7.46 ± 2.68 | 2.07 ± 0.08 | 1.65 ± 0.10 |
Data are expressed as percentage administered activity (injected dose) per gram of tissue (%ID/g) after intravenous injection of 740 kBq (20 μCi) 18F-FB-NAPamide at 1, 4, and 1-h block (with coinjection of 200 μg NDP) (n = 3). Significant inhibition of uptake was observed in B16/F10 melanoma (P < 0.05) but was not observed in A375M melanoma (P > 0.05).